About: Longitudinal profile of antibodies against SARS‐coronavirus in SARS patients and their clinical significance

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Longitudinal profile of antibodies against SARS‐coronavirus in SARS patients and their clinical significance Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Longitudinal profile of antibodies against SARS‐coronavirus in SARS patients and their clinical significance
Creator	Ke, Changwen Li, Hui Zhong, Nanshan Chen, Rongchang Lai, Kefang Zeng, Guangqiao Chan-Yeung, Moira Cai, Chaoda Mo, Hongying Ren, Xiaolan Tan, Yaxia
Source	Medline; PMC
abstract	Background: Severe acute respiratory syndrome (SARS) is a newly discovered disease caused by a novel coronavirus. The present study studied the longitudinal profile of antibodies against SARS‐coronavirus (SARS‐CoV) in SARS patients and evaluated the clinical significance of these antibodies. Methods: Two methods, ELISA and indirect immunofluorescent assay, were used for the detection of the anti‐SARS‐CoV IgG and IgM in 335 serial sera from 98 SARS patients. In 18 patients, serum antibody profiles were investigated and antibody neutralization tests were performed from 7 to 720 days after the onset of symptoms. Results: The ratios of positive IgG/IgM by ELISA were 0/0, 45.4/39.4, 88.6/71.4, 96/88, 100/48.6, 100/30.9, 100/17.1, 100/0 per cent, respectively, on 1–7, 8–14, 15–21, 22–28, 29–60, 61–90, 91–180 and 181–720 days after the onset of symptoms. Antibodies were not detected within the first 7 days of illness, but IgG titre increased dramatically on day 15, reaching a peak on day 60, and remained high until day 180 from when it declined gradually until day 720. IgM was detected on day 15 and rapidly reached a peak, then declined gradually until it was undetectable on day 180. Neutralizing viral antibodies were demonstrated in the convalescence sera from SARS patients. Conclusion: The persistence of detectable IgG antibodies and neutralizing viral antibodies for up to 720 days suggest that SARS patients may be protected from recurrent SARS‐CoV infection for up to 2 years.
has issue date	2006-01-12(xsd:dateTime)
bibo:doi	10.1111/j.1440-1843.2006.00783.x
bibo:pmid	16423201
has license	no-cc
sha1sum (hex)	b6f2d2b465870080ee39199cb6bd5ba940803a25
schema:url	https://doi.org/10.1111/j.1440-1843.2006.00783.x
resource representing a document's title	Longitudinal profile of antibodies against SARS‐coronavirus in SARS patients and their clinical significance
has PubMed Central identifier	PMC7192223
has PubMed identifier	16423201
schema:publication	Respirology
resource representing a document's body	covid:b6f2d2b465870080ee39199cb6bd5ba940803a25#body_text
is schema:about of	covid:arg/b6f2d2b465870080ee39199cb6bd5ba940803a25 named entity 'LAI' named entity 'patients' named entity 'clinical significance' named entity 'clinical significance' named entity 'SARS' named entity 'SARS-CoV' named entity 'IgG antibodies' named entity 'SPSS' named entity 'serum' named entity 'immunofluorescence assay' named entity '28 days' named entity 'GenBank' named entity 'IgM' named entity 'SARS-CoV' named entity 'IgG' named entity 'IgM antibodies' named entity 'serodiagnosis' named entity 'Blood samples' named entity 'blood samples' named entity 'SARS outbreak' named entity 'China' named entity 'IgG' named entity 'neutralization test' named entity 'antibody tests' named entity 'SARS-CoV' named entity 'antibody titres' named entity 'IgG' named entity 'virus' named entity 'antibody' named entity 'intubated' named entity 'IgG' named entity 'SPSS' named entity 'infection' named entity 'IgG' named entity 'supernatants' named entity 'IgG antibody' named entity 'oxygen' named entity 'microplate reader' named entity 'fever' named entity 'Serum samples' named entity 'Severe acute respiratory syndrome' named entity 'antibodies' named entity 'SARS-CoV' named entity 'antibody' named entity 'cytopathic effect' named entity 'serum' named entity 'coronavirus' named entity 'immune response' named entity 'CXR' named entity 'virus' named entity 'IgG' named entity 'antibodies' named entity 'lysed' named entity 'coronavirus' named entity 'FITC' named entity 'pneumonic' named entity 'IgM antibodies' named entity 'neutralizing antibodies' named entity 'atypical pneumonia' named entity 'neutralizing antibodies' named entity 'PEEP' named entity 'phosphate buffered saline' named entity 'SARS' named entity 'fluorescence' named entity 'IgG antibodies' named entity 'CXR' named entity 'SARS-CoV' named entity 'serum' named entity 'oxygen' named entity 'antigen'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software